mouse rantes Search Results


94
R&D Systems recombinant rantes protein
(A) HBEpC were cultured with cGAMP (14nM), H 2 O 2 , (100μM) or cGAMP+H 2 O 2 for 4 hours. (B-F) qPCR analysis of human IFNα (B) and IFNβ (C) and epithelial cytokines, IL-33 (D), TSLP (E), and <t>RANTES</t> (F). RANTES was stimulated by cGAMP and cGAMP+ H 2 O 2 . IFNβ was also stimulated by cGAMP+H 2 O 2 . Statistical analysis is performed by one-way ANOVA (means ± SEM, n=4). * p < 0.05, ** p < 0.01, **** p < 0.0001
Recombinant Rantes Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant rantes protein/product/R&D Systems
Average 94 stars, based on 1 article reviews
recombinant rantes protein - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

92
Sino Biological ccl5
A) Venn diagram displaying the chemokines differentially expressed in mice or human liver tumors. The number of samples for each dataset is included. Red, significantly upregulated; blue, significantly downregulated. The intersection shows the chemokines disregulated in both datasets. B) Expression of <t>CCL5</t> in 360 human HCC samples (LIHC, liver hepatocellular carcinoma, from the TCGA). Box and whisker plot, with the central line representing the median, the ends of the box representing the upper and lower quartiles, and the whiskers extending to the highest and lowest observations. Mann-Whitney test. CTNNB1 signature low (n = 120), intermediate (inter, n = 120), and high (n = 120). C) Schematic of vectors injected into mice. The transposon-based vector overexpressing CTNNB1 also expresses Ccl5. D) Survival curves in C57BL/6 WT (wild-type) females. Number of mice per group is shown as well as median survival. Log-rank Mantel-Cox test. E) Pictures of representative livers from D. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm. F-G) Quantification of the number of DC1 dendritic cells (F) or percentage of SIINFEKL-specific CD8+ T cells (G) in the livers of the corresponding mice (n = 5–7 per group). N, normal liver; CTNNB1-Ccl5, Myc-lucOS;CTNNB1-Ccl5. Mean and standard deviation (SD) are shown. Mann-Whitney test. H) Survival curves in C57BL/6 WT (wild-type) females with combined CD4+ and CD8+ T cell depletion. Number of mice per group is shown as well as median survival. Undef, undefined. Log-rank Mantel-Cox test. I) Pictures of representative livers from Figure F. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm. J-K) Survival curves in C57BL/6 WT (wild-type, WT) or Batf3−/−males (J) and females (K). Number of mice per group is shown as well as median survival. Undef, undefined. Log-rank Mantel-Cox test. L) Pictures of representative livers from Figure K. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm.
Ccl5, supplied by Sino Biological, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ccl5/product/Sino Biological
Average 92 stars, based on 1 article reviews
ccl5 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

95
R&D Systems duoset mouse ccl5 rantes elisa
A) Venn diagram displaying the chemokines differentially expressed in mice or human liver tumors. The number of samples for each dataset is included. Red, significantly upregulated; blue, significantly downregulated. The intersection shows the chemokines disregulated in both datasets. B) Expression of <t>CCL5</t> in 360 human HCC samples (LIHC, liver hepatocellular carcinoma, from the TCGA). Box and whisker plot, with the central line representing the median, the ends of the box representing the upper and lower quartiles, and the whiskers extending to the highest and lowest observations. Mann-Whitney test. CTNNB1 signature low (n = 120), intermediate (inter, n = 120), and high (n = 120). C) Schematic of vectors injected into mice. The transposon-based vector overexpressing CTNNB1 also expresses Ccl5. D) Survival curves in C57BL/6 WT (wild-type) females. Number of mice per group is shown as well as median survival. Log-rank Mantel-Cox test. E) Pictures of representative livers from D. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm. F-G) Quantification of the number of DC1 dendritic cells (F) or percentage of SIINFEKL-specific CD8+ T cells (G) in the livers of the corresponding mice (n = 5–7 per group). N, normal liver; CTNNB1-Ccl5, Myc-lucOS;CTNNB1-Ccl5. Mean and standard deviation (SD) are shown. Mann-Whitney test. H) Survival curves in C57BL/6 WT (wild-type) females with combined CD4+ and CD8+ T cell depletion. Number of mice per group is shown as well as median survival. Undef, undefined. Log-rank Mantel-Cox test. I) Pictures of representative livers from Figure F. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm. J-K) Survival curves in C57BL/6 WT (wild-type, WT) or Batf3−/−males (J) and females (K). Number of mice per group is shown as well as median survival. Undef, undefined. Log-rank Mantel-Cox test. L) Pictures of representative livers from Figure K. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm.
Duoset Mouse Ccl5 Rantes Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/duoset mouse ccl5 rantes elisa/product/R&D Systems
Average 95 stars, based on 1 article reviews
duoset mouse ccl5 rantes elisa - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

92
R&D Systems antibodies mab4781
A) Venn diagram displaying the chemokines differentially expressed in mice or human liver tumors. The number of samples for each dataset is included. Red, significantly upregulated; blue, significantly downregulated. The intersection shows the chemokines disregulated in both datasets. B) Expression of <t>CCL5</t> in 360 human HCC samples (LIHC, liver hepatocellular carcinoma, from the TCGA). Box and whisker plot, with the central line representing the median, the ends of the box representing the upper and lower quartiles, and the whiskers extending to the highest and lowest observations. Mann-Whitney test. CTNNB1 signature low (n = 120), intermediate (inter, n = 120), and high (n = 120). C) Schematic of vectors injected into mice. The transposon-based vector overexpressing CTNNB1 also expresses Ccl5. D) Survival curves in C57BL/6 WT (wild-type) females. Number of mice per group is shown as well as median survival. Log-rank Mantel-Cox test. E) Pictures of representative livers from D. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm. F-G) Quantification of the number of DC1 dendritic cells (F) or percentage of SIINFEKL-specific CD8+ T cells (G) in the livers of the corresponding mice (n = 5–7 per group). N, normal liver; CTNNB1-Ccl5, Myc-lucOS;CTNNB1-Ccl5. Mean and standard deviation (SD) are shown. Mann-Whitney test. H) Survival curves in C57BL/6 WT (wild-type) females with combined CD4+ and CD8+ T cell depletion. Number of mice per group is shown as well as median survival. Undef, undefined. Log-rank Mantel-Cox test. I) Pictures of representative livers from Figure F. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm. J-K) Survival curves in C57BL/6 WT (wild-type, WT) or Batf3−/−males (J) and females (K). Number of mice per group is shown as well as median survival. Undef, undefined. Log-rank Mantel-Cox test. L) Pictures of representative livers from Figure K. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm.
Antibodies Mab4781, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies mab4781/product/R&D Systems
Average 92 stars, based on 1 article reviews
antibodies mab4781 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

93
R&D Systems baf478
A) Venn diagram displaying the chemokines differentially expressed in mice or human liver tumors. The number of samples for each dataset is included. Red, significantly upregulated; blue, significantly downregulated. The intersection shows the chemokines disregulated in both datasets. B) Expression of <t>CCL5</t> in 360 human HCC samples (LIHC, liver hepatocellular carcinoma, from the TCGA). Box and whisker plot, with the central line representing the median, the ends of the box representing the upper and lower quartiles, and the whiskers extending to the highest and lowest observations. Mann-Whitney test. CTNNB1 signature low (n = 120), intermediate (inter, n = 120), and high (n = 120). C) Schematic of vectors injected into mice. The transposon-based vector overexpressing CTNNB1 also expresses Ccl5. D) Survival curves in C57BL/6 WT (wild-type) females. Number of mice per group is shown as well as median survival. Log-rank Mantel-Cox test. E) Pictures of representative livers from D. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm. F-G) Quantification of the number of DC1 dendritic cells (F) or percentage of SIINFEKL-specific CD8+ T cells (G) in the livers of the corresponding mice (n = 5–7 per group). N, normal liver; CTNNB1-Ccl5, Myc-lucOS;CTNNB1-Ccl5. Mean and standard deviation (SD) are shown. Mann-Whitney test. H) Survival curves in C57BL/6 WT (wild-type) females with combined CD4+ and CD8+ T cell depletion. Number of mice per group is shown as well as median survival. Undef, undefined. Log-rank Mantel-Cox test. I) Pictures of representative livers from Figure F. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm. J-K) Survival curves in C57BL/6 WT (wild-type, WT) or Batf3−/−males (J) and females (K). Number of mice per group is shown as well as median survival. Undef, undefined. Log-rank Mantel-Cox test. L) Pictures of representative livers from Figure K. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm.
Baf478, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/baf478/product/R&D Systems
Average 93 stars, based on 1 article reviews
baf478 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
R&D Systems ccl5 levels
Changes in <t>CCL5</t> and HMGB1 protein levels changes at lesion sites following rat SCI. (A) ELISA measurement of CCL5 protein levels at lesion sites following SCI at 0 d, 1 d, 4 d and 7 d, respectively. (B) Western blot analysis of HMGB1 expression following SCI at 0 d, 1 d, 4 d and 7 d. (C) Quantification data are shown in ( B ). Quantities were normalized to endogenous β-actin. (D) ELISA analysis of CCL5 protein levels at lesion sites at 0 d, 1 d, 4 d and 7 d following with or without intrathecal injection of 10 µl of an HMGB1 neutralizing antibody (HMGB1 Ab, 50 µg/kg). (E) Immunofluorescence staining revealed the colocalization of CCL5 with GFAP-positive astrocytes before or after SCI at 4 d with or without the intrathecal injection of 10 µl of HMGB1 Ab (50 µg/kg). The rectangle indicates the region magnified. Arrowheads indicate positive signals. n = 6. Scale bars, 50 μm in (E) . The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01).
Ccl5 Levels, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ccl5 levels/product/R&D Systems
Average 93 stars, based on 1 article reviews
ccl5 levels - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

96
R&D Systems mab478

Mab478, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mab478/product/R&D Systems
Average 96 stars, based on 1 article reviews
mab478 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

94
R&D Systems rantes

Rantes, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rantes/product/R&D Systems
Average 94 stars, based on 1 article reviews
rantes - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
R&D Systems recombinant mouse ccl5 rantes

Recombinant Mouse Ccl5 Rantes, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse ccl5 rantes/product/R&D Systems
Average 94 stars, based on 1 article reviews
recombinant mouse ccl5 rantes - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
R&D Systems mouse ccl5 rantes duoset elisa
Inhibition of HIF-1α trancription activity impairs the hypoxia-induced ACKR2 expression and increases <t>CCL5</t> levels in B16-F10 melanoma cells. ( A ) Western-blot analysis of HIF-1α protein expression in B16-F10 CTRL and HIFΔ cells cultured in normoxia (21% O - N) or hypoxia (0.1% O - H) for 48 h. The full-length blot is available in Supplementary Fig. . Actin was used as a loading control. ( B ) ACKR2 protein expression analysis by flow cytometry in permeabilized B16-F10 CTRL and HIFΔ cells cultured in normoxia (21% O - N) or hypoxia (0.1% O - H) for 48 h. Results are reported as the percentage of positive live cells and represent the average of three independent experiments. Error bars indicate mean ± SEM. * = p < 0.05, ** = p < 0.01, and *** = p < 0.001, determined by one-way ANOVA test. ( C ) RT-qPCR quantification of Ackr2 , Ca9 , and Vegfa mRNA levels in cells described in ( B ). Ca9 and Vegfa gene expressions were analyzed to confirm the induction of hypoxic conditions. Results are reported as fold change (FC) and represent the average of three independent experiments. Error bars indicate mean ± SEM. ns = not significant, * = p < 0.05, and ** = p < 0.01, determined by unpaired two-tailed Student’s t test. ( D ) ELISA quantification of CCL5 protein levels in the supernatant of cells described in ( B ) and ( C ). Results are reported as pg/ml and represent the average of three independent experiments. Error bars indicate mean ± SEM. * = p < 0.05 and *** = p < 0.001, determined by one-way ANOVA test.
Mouse Ccl5 Rantes Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse ccl5 rantes duoset elisa/product/R&D Systems
Average 94 stars, based on 1 article reviews
mouse ccl5 rantes duoset elisa - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

91
R&D Systems cc15
Inhibition of HIF-1α trancription activity impairs the hypoxia-induced ACKR2 expression and increases <t>CCL5</t> levels in B16-F10 melanoma cells. ( A ) Western-blot analysis of HIF-1α protein expression in B16-F10 CTRL and HIFΔ cells cultured in normoxia (21% O - N) or hypoxia (0.1% O - H) for 48 h. The full-length blot is available in Supplementary Fig. . Actin was used as a loading control. ( B ) ACKR2 protein expression analysis by flow cytometry in permeabilized B16-F10 CTRL and HIFΔ cells cultured in normoxia (21% O - N) or hypoxia (0.1% O - H) for 48 h. Results are reported as the percentage of positive live cells and represent the average of three independent experiments. Error bars indicate mean ± SEM. * = p < 0.05, ** = p < 0.01, and *** = p < 0.001, determined by one-way ANOVA test. ( C ) RT-qPCR quantification of Ackr2 , Ca9 , and Vegfa mRNA levels in cells described in ( B ). Ca9 and Vegfa gene expressions were analyzed to confirm the induction of hypoxic conditions. Results are reported as fold change (FC) and represent the average of three independent experiments. Error bars indicate mean ± SEM. ns = not significant, * = p < 0.05, and ** = p < 0.01, determined by unpaired two-tailed Student’s t test. ( D ) ELISA quantification of CCL5 protein levels in the supernatant of cells described in ( B ) and ( C ). Results are reported as pg/ml and represent the average of three independent experiments. Error bars indicate mean ± SEM. * = p < 0.05 and *** = p < 0.001, determined by one-way ANOVA test.
Cc15, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cc15/product/R&D Systems
Average 91 stars, based on 1 article reviews
cc15 - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

93
Boster Bio mouse rantes elisa kit
The Arf1 inhibitors promote T-cell infiltration by upregulating <t>CCL5</t> <t>chemokine.</t> (a) Chord diagram of gene correlation in the Arf1-ablated MYC-ON liver tumors ( n = 4 in each group). (b) qRT-PCR for chemokines in CT26 cells treated with DMSO, DU101, or DU102. (c) Serum CCL5 levels in the CT26 allografts with the indicated treatments ( n = 6 in each group). (d) CCL5 mRNA levels in the liver tumors of MYC-ON mice that were treated with DMSO, DU101, or DU102 ( n = 9 in each group). (e) Experimental design for the co-culture system. (f) FACS analysis of the migration of CD3 + T cells in CT26 cells that were treated with DMSO, DU101, or DU102. (g) The mRNA levels of CCL5 in CT26 cells with the indicated knockdowns and treatments. (h) FACS analysis of CD3 + T-cell migration in CT26 cells with the indicated knockdowns and treatments. (i and j) Tumor volumes (i) and tumor weights (j) of CT26 allografts with the indicated knockdowns and treatments ( n = 10 in each group). (k) Percentages of infiltrated CD3 + T cells in CT26 allografts with the indicated knockdowns and treatments ( n = 3 in each group). Data are shown as mean ± SEM. Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. n.s., no significance.
Mouse Rantes Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse rantes elisa kit/product/Boster Bio
Average 93 stars, based on 1 article reviews
mouse rantes elisa kit - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


(A) HBEpC were cultured with cGAMP (14nM), H 2 O 2 , (100μM) or cGAMP+H 2 O 2 for 4 hours. (B-F) qPCR analysis of human IFNα (B) and IFNβ (C) and epithelial cytokines, IL-33 (D), TSLP (E), and RANTES (F). RANTES was stimulated by cGAMP and cGAMP+ H 2 O 2 . IFNβ was also stimulated by cGAMP+H 2 O 2 . Statistical analysis is performed by one-way ANOVA (means ± SEM, n=4). * p < 0.05, ** p < 0.01, **** p < 0.0001

Journal: bioRxiv

Article Title: STING/RANTES Pathway in Airway Epithelium Stimulates Sensitization to Der p1 in an Asthma Model

doi: 10.1101/2023.07.30.550251

Figure Lengend Snippet: (A) HBEpC were cultured with cGAMP (14nM), H 2 O 2 , (100μM) or cGAMP+H 2 O 2 for 4 hours. (B-F) qPCR analysis of human IFNα (B) and IFNβ (C) and epithelial cytokines, IL-33 (D), TSLP (E), and RANTES (F). RANTES was stimulated by cGAMP and cGAMP+ H 2 O 2 . IFNβ was also stimulated by cGAMP+H 2 O 2 . Statistical analysis is performed by one-way ANOVA (means ± SEM, n=4). * p < 0.05, ** p < 0.01, **** p < 0.0001

Article Snippet: To elucidate the role of RANTES as an adjuvant during sensitization, the mice were sensitized with recombinant RANTES protein (R&D systems, Minneapolis, MN, USA, 478-MR) and 1 μg of HDM on Day 1.

Techniques: Cell Culture

(A) 8 weeks mice were treated with 20 ng of RANTES with 1 μg of HDM or 1 μg of HDM intra nasally on Day 1. Mice were challenged with 1 μg of HDM intranasally on Day 7, then lungs were extracted and analyzed on Day 8. (B) Pictures of lung sections of control and RANTES-adjuvanted, HDM-sensitized mice stained with H-E. Scale bar: 200 μm. Scale bar in picture of high magnification view: 40 μm. (C) Number of cells between bronchus and alveoli analyzed by ImageJ. Statistical analysis is performed by ordinary Mann Whitney’s U test (means ± SEM, 3 points/ section, n=5). (D) Pictures of lung sections in PBS and RANES-adjuvanted, HDM-sensitized mouse stained with PAS/Alcian blue. Scale bar: 80 μm. (E) Ratio of PAS/Alcianble area per epithelial cells (%). **** p < 0.0001

Journal: bioRxiv

Article Title: STING/RANTES Pathway in Airway Epithelium Stimulates Sensitization to Der p1 in an Asthma Model

doi: 10.1101/2023.07.30.550251

Figure Lengend Snippet: (A) 8 weeks mice were treated with 20 ng of RANTES with 1 μg of HDM or 1 μg of HDM intra nasally on Day 1. Mice were challenged with 1 μg of HDM intranasally on Day 7, then lungs were extracted and analyzed on Day 8. (B) Pictures of lung sections of control and RANTES-adjuvanted, HDM-sensitized mice stained with H-E. Scale bar: 200 μm. Scale bar in picture of high magnification view: 40 μm. (C) Number of cells between bronchus and alveoli analyzed by ImageJ. Statistical analysis is performed by ordinary Mann Whitney’s U test (means ± SEM, 3 points/ section, n=5). (D) Pictures of lung sections in PBS and RANES-adjuvanted, HDM-sensitized mouse stained with PAS/Alcian blue. Scale bar: 80 μm. (E) Ratio of PAS/Alcianble area per epithelial cells (%). **** p < 0.0001

Article Snippet: To elucidate the role of RANTES as an adjuvant during sensitization, the mice were sensitized with recombinant RANTES protein (R&D systems, Minneapolis, MN, USA, 478-MR) and 1 μg of HDM on Day 1.

Techniques: Control, Staining

A) Venn diagram displaying the chemokines differentially expressed in mice or human liver tumors. The number of samples for each dataset is included. Red, significantly upregulated; blue, significantly downregulated. The intersection shows the chemokines disregulated in both datasets. B) Expression of CCL5 in 360 human HCC samples (LIHC, liver hepatocellular carcinoma, from the TCGA). Box and whisker plot, with the central line representing the median, the ends of the box representing the upper and lower quartiles, and the whiskers extending to the highest and lowest observations. Mann-Whitney test. CTNNB1 signature low (n = 120), intermediate (inter, n = 120), and high (n = 120). C) Schematic of vectors injected into mice. The transposon-based vector overexpressing CTNNB1 also expresses Ccl5. D) Survival curves in C57BL/6 WT (wild-type) females. Number of mice per group is shown as well as median survival. Log-rank Mantel-Cox test. E) Pictures of representative livers from D. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm. F-G) Quantification of the number of DC1 dendritic cells (F) or percentage of SIINFEKL-specific CD8+ T cells (G) in the livers of the corresponding mice (n = 5–7 per group). N, normal liver; CTNNB1-Ccl5, Myc-lucOS;CTNNB1-Ccl5. Mean and standard deviation (SD) are shown. Mann-Whitney test. H) Survival curves in C57BL/6 WT (wild-type) females with combined CD4+ and CD8+ T cell depletion. Number of mice per group is shown as well as median survival. Undef, undefined. Log-rank Mantel-Cox test. I) Pictures of representative livers from Figure F. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm. J-K) Survival curves in C57BL/6 WT (wild-type, WT) or Batf3−/−males (J) and females (K). Number of mice per group is shown as well as median survival. Undef, undefined. Log-rank Mantel-Cox test. L) Pictures of representative livers from Figure K. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm.

Journal: Cancer discovery

Article Title: β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma

doi: 10.1158/2159-8290.CD-19-0074

Figure Lengend Snippet: A) Venn diagram displaying the chemokines differentially expressed in mice or human liver tumors. The number of samples for each dataset is included. Red, significantly upregulated; blue, significantly downregulated. The intersection shows the chemokines disregulated in both datasets. B) Expression of CCL5 in 360 human HCC samples (LIHC, liver hepatocellular carcinoma, from the TCGA). Box and whisker plot, with the central line representing the median, the ends of the box representing the upper and lower quartiles, and the whiskers extending to the highest and lowest observations. Mann-Whitney test. CTNNB1 signature low (n = 120), intermediate (inter, n = 120), and high (n = 120). C) Schematic of vectors injected into mice. The transposon-based vector overexpressing CTNNB1 also expresses Ccl5. D) Survival curves in C57BL/6 WT (wild-type) females. Number of mice per group is shown as well as median survival. Log-rank Mantel-Cox test. E) Pictures of representative livers from D. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm. F-G) Quantification of the number of DC1 dendritic cells (F) or percentage of SIINFEKL-specific CD8+ T cells (G) in the livers of the corresponding mice (n = 5–7 per group). N, normal liver; CTNNB1-Ccl5, Myc-lucOS;CTNNB1-Ccl5. Mean and standard deviation (SD) are shown. Mann-Whitney test. H) Survival curves in C57BL/6 WT (wild-type) females with combined CD4+ and CD8+ T cell depletion. Number of mice per group is shown as well as median survival. Undef, undefined. Log-rank Mantel-Cox test. I) Pictures of representative livers from Figure F. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm. J-K) Survival curves in C57BL/6 WT (wild-type, WT) or Batf3−/−males (J) and females (K). Number of mice per group is shown as well as median survival. Undef, undefined. Log-rank Mantel-Cox test. L) Pictures of representative livers from Figure K. The number indicates the number of days from injection to death for that particular mouse. Scale bar represents 1 cm.

Article Snippet: The full-length cDNA of Ccl5 was obtained from Sino Biological (plasmid reference: MG50022-M).

Techniques: Expressing, Whisker Assay, MANN-WHITNEY, Injection, Plasmid Preparation, Standard Deviation

Changes in CCL5 and HMGB1 protein levels changes at lesion sites following rat SCI. (A) ELISA measurement of CCL5 protein levels at lesion sites following SCI at 0 d, 1 d, 4 d and 7 d, respectively. (B) Western blot analysis of HMGB1 expression following SCI at 0 d, 1 d, 4 d and 7 d. (C) Quantification data are shown in ( B ). Quantities were normalized to endogenous β-actin. (D) ELISA analysis of CCL5 protein levels at lesion sites at 0 d, 1 d, 4 d and 7 d following with or without intrathecal injection of 10 µl of an HMGB1 neutralizing antibody (HMGB1 Ab, 50 µg/kg). (E) Immunofluorescence staining revealed the colocalization of CCL5 with GFAP-positive astrocytes before or after SCI at 4 d with or without the intrathecal injection of 10 µl of HMGB1 Ab (50 µg/kg). The rectangle indicates the region magnified. Arrowheads indicate positive signals. n = 6. Scale bars, 50 μm in (E) . The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01).

Journal: Scientific Reports

Article Title: High mobility group box-1 protein promotes astrocytic CCL5 production through the MAPK/NF-κB pathway following spinal cord injury

doi: 10.1038/s41598-024-72947-2

Figure Lengend Snippet: Changes in CCL5 and HMGB1 protein levels changes at lesion sites following rat SCI. (A) ELISA measurement of CCL5 protein levels at lesion sites following SCI at 0 d, 1 d, 4 d and 7 d, respectively. (B) Western blot analysis of HMGB1 expression following SCI at 0 d, 1 d, 4 d and 7 d. (C) Quantification data are shown in ( B ). Quantities were normalized to endogenous β-actin. (D) ELISA analysis of CCL5 protein levels at lesion sites at 0 d, 1 d, 4 d and 7 d following with or without intrathecal injection of 10 µl of an HMGB1 neutralizing antibody (HMGB1 Ab, 50 µg/kg). (E) Immunofluorescence staining revealed the colocalization of CCL5 with GFAP-positive astrocytes before or after SCI at 4 d with or without the intrathecal injection of 10 µl of HMGB1 Ab (50 µg/kg). The rectangle indicates the region magnified. Arrowheads indicate positive signals. n = 6. Scale bars, 50 μm in (E) . The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01).

Article Snippet: The lysates were centrifuged at 12,000×g for 15 min. CCL5 levels (R&D systems, cat. no. MMR00) were assessed via ELISA kits according to the manufacturer’s directions.

Techniques: Enzyme-linked Immunosorbent Assay, Western Blot, Expressing, Injection, Immunofluorescence, Staining, Standard Deviation

Examination of CCL5 production in astrocytes following stimulation with rHMGB1. ( A , B ) Purified primary astrocytes were stained with GFAP and Hoechst 33,342, and the purity was greater than 90%. Scale bar, 50 μm. ( C , D ) ELISA analysis of CCL5 in the lysates and supernatants of primary astrocytes following stimulation with 0–2.5 µg/mL rat recombinant HMGB1 (rHMGB1) for 24 h, respectively. ( E , F ) ELISA assay was used to determine the production of CCL5 in the lysates and supernatants following primary astrocyte treatment with 0.5 µg/ml rHMGB1 in the presence of 2.5 µg/ml HMGB1 Ab, respectively. The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01, *** P < 0.001).

Journal: Scientific Reports

Article Title: High mobility group box-1 protein promotes astrocytic CCL5 production through the MAPK/NF-κB pathway following spinal cord injury

doi: 10.1038/s41598-024-72947-2

Figure Lengend Snippet: Examination of CCL5 production in astrocytes following stimulation with rHMGB1. ( A , B ) Purified primary astrocytes were stained with GFAP and Hoechst 33,342, and the purity was greater than 90%. Scale bar, 50 μm. ( C , D ) ELISA analysis of CCL5 in the lysates and supernatants of primary astrocytes following stimulation with 0–2.5 µg/mL rat recombinant HMGB1 (rHMGB1) for 24 h, respectively. ( E , F ) ELISA assay was used to determine the production of CCL5 in the lysates and supernatants following primary astrocyte treatment with 0.5 µg/ml rHMGB1 in the presence of 2.5 µg/ml HMGB1 Ab, respectively. The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01, *** P < 0.001).

Article Snippet: The lysates were centrifuged at 12,000×g for 15 min. CCL5 levels (R&D systems, cat. no. MMR00) were assessed via ELISA kits according to the manufacturer’s directions.

Techniques: Purification, Staining, Enzyme-linked Immunosorbent Assay, Recombinant, Standard Deviation

Effects of RAGE, TLR-2, or TLR-4 interference on HMGB1-induced CCL5 production in astrocytes. ( A , B ) Cell lysates and supernatants were tested by ELISA for the production of CCL5, following astrocyte treatment with 0.5 µg/ml rHMGB1 in the presence of the RAGE inhibitor FPS-ZM1 (2 µM) for 24 h. ( D , E ) ELISA was used to determine CCL5 protein levels in lysates and supernatants from astrocytes after stimulation with 0.5 µg/ml rHMGB1 in the presence of the TLR2 inhibitor C29 (10 µM) for 24 h. ( G , H ) CCL5 levels in lysates and supernatants of astrocytes were determined by ELISA after the astrocytes were treated with the TLR4 inhibitor TAK-242 (2 µM) in the presence of 0.5 µg/ml rHMGB1 for 24 h. ( C , F , I ) CCK8 assay of the effects of FPS-ZM1, C29, or TAK-242 on the viability of astrocytes. The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01).

Journal: Scientific Reports

Article Title: High mobility group box-1 protein promotes astrocytic CCL5 production through the MAPK/NF-κB pathway following spinal cord injury

doi: 10.1038/s41598-024-72947-2

Figure Lengend Snippet: Effects of RAGE, TLR-2, or TLR-4 interference on HMGB1-induced CCL5 production in astrocytes. ( A , B ) Cell lysates and supernatants were tested by ELISA for the production of CCL5, following astrocyte treatment with 0.5 µg/ml rHMGB1 in the presence of the RAGE inhibitor FPS-ZM1 (2 µM) for 24 h. ( D , E ) ELISA was used to determine CCL5 protein levels in lysates and supernatants from astrocytes after stimulation with 0.5 µg/ml rHMGB1 in the presence of the TLR2 inhibitor C29 (10 µM) for 24 h. ( G , H ) CCL5 levels in lysates and supernatants of astrocytes were determined by ELISA after the astrocytes were treated with the TLR4 inhibitor TAK-242 (2 µM) in the presence of 0.5 µg/ml rHMGB1 for 24 h. ( C , F , I ) CCK8 assay of the effects of FPS-ZM1, C29, or TAK-242 on the viability of astrocytes. The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01).

Article Snippet: The lysates were centrifuged at 12,000×g for 15 min. CCL5 levels (R&D systems, cat. no. MMR00) were assessed via ELISA kits according to the manufacturer’s directions.

Techniques: Enzyme-linked Immunosorbent Assay, CCK-8 Assay, Standard Deviation

Determination of CCL5 synthesis-related protein levels in astrocytes following stimulation with rHMGB1. (A) Western blot analysis of the phosphorylation of the ERK, JNK, P38 kinase and p65NF-κB proteins after astrocytes were treated with 0–2.5 µg/mL rHMGB1 for 24 h. (B-E) Quantification data are shown in (A). Quantities were normalized to endogenous β-actin. The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01, *** P < 0.001).

Journal: Scientific Reports

Article Title: High mobility group box-1 protein promotes astrocytic CCL5 production through the MAPK/NF-κB pathway following spinal cord injury

doi: 10.1038/s41598-024-72947-2

Figure Lengend Snippet: Determination of CCL5 synthesis-related protein levels in astrocytes following stimulation with rHMGB1. (A) Western blot analysis of the phosphorylation of the ERK, JNK, P38 kinase and p65NF-κB proteins after astrocytes were treated with 0–2.5 µg/mL rHMGB1 for 24 h. (B-E) Quantification data are shown in (A). Quantities were normalized to endogenous β-actin. The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01, *** P < 0.001).

Article Snippet: The lysates were centrifuged at 12,000×g for 15 min. CCL5 levels (R&D systems, cat. no. MMR00) were assessed via ELISA kits according to the manufacturer’s directions.

Techniques: Western Blot, Standard Deviation

Effects of the inhibition of MAPK/NF-κB signaling on the HMGB1-induced production of CCL5 from astrocytes. ( A , B ) ELISA was used to determine the effects of 10 µM ERK inhibitor PD98059, 10 µM JNK inhibitor SP6001251 or 10 µM P38 inhibitor SB203580 in the presence of 0.5 µg/ml rHMGB1 for 24 h on CCL5 protein production levels in lysates and supernatants of astrocytes. (C) Western blot analysis of the activation of p65NFκB protein after astrocyte treatment with 10 µM ERK inhibitor PD98059 or 10 µM JNK inhibitor SP6001251 for 24 h in the presence of 0.5 µg/ml rHMGB1. (D) Quantification data are shown in (C). Quantities were normalized to endogenous β-actin. ( E , F ) ELISA analysis of CCL5 in the lysates and supernatants of primary astrocytes following challenge with 10 µM SN50 for 24 h in the presence of 0.5 µg/ml rHMGB1, respectively. The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01, *** P < 0.001).

Journal: Scientific Reports

Article Title: High mobility group box-1 protein promotes astrocytic CCL5 production through the MAPK/NF-κB pathway following spinal cord injury

doi: 10.1038/s41598-024-72947-2

Figure Lengend Snippet: Effects of the inhibition of MAPK/NF-κB signaling on the HMGB1-induced production of CCL5 from astrocytes. ( A , B ) ELISA was used to determine the effects of 10 µM ERK inhibitor PD98059, 10 µM JNK inhibitor SP6001251 or 10 µM P38 inhibitor SB203580 in the presence of 0.5 µg/ml rHMGB1 for 24 h on CCL5 protein production levels in lysates and supernatants of astrocytes. (C) Western blot analysis of the activation of p65NFκB protein after astrocyte treatment with 10 µM ERK inhibitor PD98059 or 10 µM JNK inhibitor SP6001251 for 24 h in the presence of 0.5 µg/ml rHMGB1. (D) Quantification data are shown in (C). Quantities were normalized to endogenous β-actin. ( E , F ) ELISA analysis of CCL5 in the lysates and supernatants of primary astrocytes following challenge with 10 µM SN50 for 24 h in the presence of 0.5 µg/ml rHMGB1, respectively. The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01, *** P < 0.001).

Article Snippet: The lysates were centrifuged at 12,000×g for 15 min. CCL5 levels (R&D systems, cat. no. MMR00) were assessed via ELISA kits according to the manufacturer’s directions.

Techniques: Inhibition, Enzyme-linked Immunosorbent Assay, Western Blot, Activation Assay, Standard Deviation

Effects of HMGB1-mediated astrocytic CCL5 on the migration of BV2 microglia cells or RAW 264.7 macrophage cells in vitro. (A) Illustration of the BV2 or RAW 264.7 cells with rCCL5 coculture model. (B) Transwell assay analysis of migration the ability of BV2 or RAW 264.7 cells co-incubated with 0.1 µg/ml rCCL5 for 48 h. ( C ) and ( D ) Quantification data are shown in (B). (E) Illustration of the BV2 or RAW 264.7 cells and ACM coculture model. (F) Migration assay of BV2 or RAW 264.7 cells cocultured with ACM. ACM were prepared from astrocytes exposed to 0.5 µg/ml rHMGB1 for 24 h, followed by the supernatant was collected and incubated with 2.5 µg/ml IgG or CCL5 Ab for 4 h. (G) and (H) Quantification data are shown in (F). Scale bars, 100 μm in ( B ) and ( F ). The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01, *** P < 0.001).

Journal: Scientific Reports

Article Title: High mobility group box-1 protein promotes astrocytic CCL5 production through the MAPK/NF-κB pathway following spinal cord injury

doi: 10.1038/s41598-024-72947-2

Figure Lengend Snippet: Effects of HMGB1-mediated astrocytic CCL5 on the migration of BV2 microglia cells or RAW 264.7 macrophage cells in vitro. (A) Illustration of the BV2 or RAW 264.7 cells with rCCL5 coculture model. (B) Transwell assay analysis of migration the ability of BV2 or RAW 264.7 cells co-incubated with 0.1 µg/ml rCCL5 for 48 h. ( C ) and ( D ) Quantification data are shown in (B). (E) Illustration of the BV2 or RAW 264.7 cells and ACM coculture model. (F) Migration assay of BV2 or RAW 264.7 cells cocultured with ACM. ACM were prepared from astrocytes exposed to 0.5 µg/ml rHMGB1 for 24 h, followed by the supernatant was collected and incubated with 2.5 µg/ml IgG or CCL5 Ab for 4 h. (G) and (H) Quantification data are shown in (F). Scale bars, 100 μm in ( B ) and ( F ). The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01, *** P < 0.001).

Article Snippet: The lysates were centrifuged at 12,000×g for 15 min. CCL5 levels (R&D systems, cat. no. MMR00) were assessed via ELISA kits according to the manufacturer’s directions.

Techniques: Migration, In Vitro, Transwell Assay, Incubation, Standard Deviation

Effects of HMGB1-induced astrocytic CCL5 on microglia/macrophage polarization. ( A ) and ( B ) qRT-PCR was used to determine the expression of M1 markers ( CD86 , iNOS and TNF-a ) and M2 markers ( CD206 , Arg1 and Ym1 ) after BV2 or RAW 264.7 cells incubated with 0.1 µg/ml rCCL5 for 24 h. ( C ) and ( D ) The expression levels of M1 and M2 markers were determined by qRT-PCR following BV2 or RAW 264.7 cells cocultured with ACM for 24 h. ACM was prepared by astrocytes challenge with 0.5 µg/ml rHMGB1 for 24 h, after which the supernatant was collected and incubated with 2.5 µg/ml IgG or CCL5 Ab for 4 h. The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01, *** P < 0.001).

Journal: Scientific Reports

Article Title: High mobility group box-1 protein promotes astrocytic CCL5 production through the MAPK/NF-κB pathway following spinal cord injury

doi: 10.1038/s41598-024-72947-2

Figure Lengend Snippet: Effects of HMGB1-induced astrocytic CCL5 on microglia/macrophage polarization. ( A ) and ( B ) qRT-PCR was used to determine the expression of M1 markers ( CD86 , iNOS and TNF-a ) and M2 markers ( CD206 , Arg1 and Ym1 ) after BV2 or RAW 264.7 cells incubated with 0.1 µg/ml rCCL5 for 24 h. ( C ) and ( D ) The expression levels of M1 and M2 markers were determined by qRT-PCR following BV2 or RAW 264.7 cells cocultured with ACM for 24 h. ACM was prepared by astrocytes challenge with 0.5 µg/ml rHMGB1 for 24 h, after which the supernatant was collected and incubated with 2.5 µg/ml IgG or CCL5 Ab for 4 h. The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01, *** P < 0.001).

Article Snippet: The lysates were centrifuged at 12,000×g for 15 min. CCL5 levels (R&D systems, cat. no. MMR00) were assessed via ELISA kits according to the manufacturer’s directions.

Techniques: Quantitative RT-PCR, Expressing, Incubation, Standard Deviation

Immunofluorescence of microglia/macrophage and locomotor function assessment after the inhibition of HMGB1 or CCL5 by neutralizing antibodies in rat SCI. ( A ) Immunofluorescence of IBA1- or CD68-positive cells at 4 d following SCI after neutralizing antibody application by intrathecal injection of 10 µl of neutralizing antibodies (HMGB1 Ab, 50 µg/kg), CCL5 (CCL5 Ab, 50 µg/kg) or normal rabbit IgG (IgG, 50 µg/kg). n = 6. Scale bars, 50 μm. ( B , C ) Quantitative analysis of the intensity of IBA1- or CD68-labeled cells in ( A) , respectively. (D) HE staining of the injured spinal cord at 21 d after administration of 10 µl of HMGB1, CCL5 neutralizing antibodies or normal rabbit IgG. n = 6. Scale bars, 500 μm. (E) Quantification data are shown in ( D) . (F) Basso, Beattie, and Bresnahan (BBB) locomotor scale scores for hindlimb motor function in rats at 0 d, 7 d, 14 d, 21 d and 28 d following the intrathecal administration of the HMGB1 Ab, CCL5 Ab or normal rabbit IgG. n = 6. The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01, *** P < 0.001).

Journal: Scientific Reports

Article Title: High mobility group box-1 protein promotes astrocytic CCL5 production through the MAPK/NF-κB pathway following spinal cord injury

doi: 10.1038/s41598-024-72947-2

Figure Lengend Snippet: Immunofluorescence of microglia/macrophage and locomotor function assessment after the inhibition of HMGB1 or CCL5 by neutralizing antibodies in rat SCI. ( A ) Immunofluorescence of IBA1- or CD68-positive cells at 4 d following SCI after neutralizing antibody application by intrathecal injection of 10 µl of neutralizing antibodies (HMGB1 Ab, 50 µg/kg), CCL5 (CCL5 Ab, 50 µg/kg) or normal rabbit IgG (IgG, 50 µg/kg). n = 6. Scale bars, 50 μm. ( B , C ) Quantitative analysis of the intensity of IBA1- or CD68-labeled cells in ( A) , respectively. (D) HE staining of the injured spinal cord at 21 d after administration of 10 µl of HMGB1, CCL5 neutralizing antibodies or normal rabbit IgG. n = 6. Scale bars, 500 μm. (E) Quantification data are shown in ( D) . (F) Basso, Beattie, and Bresnahan (BBB) locomotor scale scores for hindlimb motor function in rats at 0 d, 7 d, 14 d, 21 d and 28 d following the intrathecal administration of the HMGB1 Ab, CCL5 Ab or normal rabbit IgG. n = 6. The experiments were performed in triplicate. The error bars represent the standard deviation (* P < 0.05, ** P < 0.01, *** P < 0.001).

Article Snippet: The lysates were centrifuged at 12,000×g for 15 min. CCL5 levels (R&D systems, cat. no. MMR00) were assessed via ELISA kits according to the manufacturer’s directions.

Techniques: Immunofluorescence, Inhibition, Injection, Labeling, Staining, Standard Deviation

Mechanistic diagram of HMGB1-mediated astrocytic CCL5 contributes to microglia/macrophages activation and recruitment.

Journal: Scientific Reports

Article Title: High mobility group box-1 protein promotes astrocytic CCL5 production through the MAPK/NF-κB pathway following spinal cord injury

doi: 10.1038/s41598-024-72947-2

Figure Lengend Snippet: Mechanistic diagram of HMGB1-mediated astrocytic CCL5 contributes to microglia/macrophages activation and recruitment.

Article Snippet: The lysates were centrifuged at 12,000×g for 15 min. CCL5 levels (R&D systems, cat. no. MMR00) were assessed via ELISA kits according to the manufacturer’s directions.

Techniques: Activation Assay

Journal: Cell

Article Title: NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

doi: 10.1016/j.cell.2018.01.004

Figure Lengend Snippet:

Article Snippet: For neutralization of CCL5 and XCL1, 50μg of anti-CCL5 and 50μg of anti-XCL1 antibodies or of isotype-matched control antibodies were injected i.v. at the time of tumor transplantation, followed by a second injection two days later (R&D Systems; CCL5: AF478 and MAB478; XCL1: AF486, MAB486; Isotype controls: AB-108-C, MAB006).

Techniques: Virus, Staining, Control, Recombinant, Plasmid Preparation, Software

Inhibition of HIF-1α trancription activity impairs the hypoxia-induced ACKR2 expression and increases CCL5 levels in B16-F10 melanoma cells. ( A ) Western-blot analysis of HIF-1α protein expression in B16-F10 CTRL and HIFΔ cells cultured in normoxia (21% O - N) or hypoxia (0.1% O - H) for 48 h. The full-length blot is available in Supplementary Fig. . Actin was used as a loading control. ( B ) ACKR2 protein expression analysis by flow cytometry in permeabilized B16-F10 CTRL and HIFΔ cells cultured in normoxia (21% O - N) or hypoxia (0.1% O - H) for 48 h. Results are reported as the percentage of positive live cells and represent the average of three independent experiments. Error bars indicate mean ± SEM. * = p < 0.05, ** = p < 0.01, and *** = p < 0.001, determined by one-way ANOVA test. ( C ) RT-qPCR quantification of Ackr2 , Ca9 , and Vegfa mRNA levels in cells described in ( B ). Ca9 and Vegfa gene expressions were analyzed to confirm the induction of hypoxic conditions. Results are reported as fold change (FC) and represent the average of three independent experiments. Error bars indicate mean ± SEM. ns = not significant, * = p < 0.05, and ** = p < 0.01, determined by unpaired two-tailed Student’s t test. ( D ) ELISA quantification of CCL5 protein levels in the supernatant of cells described in ( B ) and ( C ). Results are reported as pg/ml and represent the average of three independent experiments. Error bars indicate mean ± SEM. * = p < 0.05 and *** = p < 0.001, determined by one-way ANOVA test.

Journal: Scientific Reports

Article Title: Atypical chemokine receptor 2 expression is directly regulated by hypoxia inducible factor-1 alpha in cancer cells under hypoxia

doi: 10.1038/s41598-024-77628-8

Figure Lengend Snippet: Inhibition of HIF-1α trancription activity impairs the hypoxia-induced ACKR2 expression and increases CCL5 levels in B16-F10 melanoma cells. ( A ) Western-blot analysis of HIF-1α protein expression in B16-F10 CTRL and HIFΔ cells cultured in normoxia (21% O - N) or hypoxia (0.1% O - H) for 48 h. The full-length blot is available in Supplementary Fig. . Actin was used as a loading control. ( B ) ACKR2 protein expression analysis by flow cytometry in permeabilized B16-F10 CTRL and HIFΔ cells cultured in normoxia (21% O - N) or hypoxia (0.1% O - H) for 48 h. Results are reported as the percentage of positive live cells and represent the average of three independent experiments. Error bars indicate mean ± SEM. * = p < 0.05, ** = p < 0.01, and *** = p < 0.001, determined by one-way ANOVA test. ( C ) RT-qPCR quantification of Ackr2 , Ca9 , and Vegfa mRNA levels in cells described in ( B ). Ca9 and Vegfa gene expressions were analyzed to confirm the induction of hypoxic conditions. Results are reported as fold change (FC) and represent the average of three independent experiments. Error bars indicate mean ± SEM. ns = not significant, * = p < 0.05, and ** = p < 0.01, determined by unpaired two-tailed Student’s t test. ( D ) ELISA quantification of CCL5 protein levels in the supernatant of cells described in ( B ) and ( C ). Results are reported as pg/ml and represent the average of three independent experiments. Error bars indicate mean ± SEM. * = p < 0.05 and *** = p < 0.001, determined by one-way ANOVA test.

Article Snippet: ELISAs were performed using DuoSet ELISA Ancillary Reagent Kit 2 (R&D Systems, DY008B) and Mouse CCL5/RANTES DuoSet ELISA (R&D Systems, DY478) following the protocol provided by the supplier.

Techniques: Inhibition, Activity Assay, Expressing, Western Blot, Cell Culture, Control, Flow Cytometry, Quantitative RT-PCR, Two Tailed Test, Enzyme-linked Immunosorbent Assay

ACKR2 expression is decreased in B16-F10 HIFΔ tumors and associated with increased CCL5 levels. ( A ) RT-qPCR analysis of Ackr2, Ccl5, Vegfa and Ca9 gene expression in B16-F10 CTRL and HIFΔ tumors. Results are reported as fold change (FC) with error bars representing the mean ± SEM of 3 tumors per group. * = p-value < 0.05 and **** = p -value < 0.0001, determined by unpaired Student’s t-test. ( B ) Immunohistochemistry images of ACKR2 and CCL5 staining (in red), in B16-F10 CTRL and HIFΔ tumors used in ( A ). Scale bars: 200 μm. ( C ) Quantification of ACKR2 and CCL5 staining by immunohistochemistry on B16-F10 CTRL and HIFΔ tumors described in ( A ) and ( B ). Results are reported as percentage of positively stained cells relative to total cell count. For quantification, three random areas of three tumors per group were analyzed and averaged. Error bars represent the mean ± SEM of 3 tumors per group. * = p -value < 0.05 determined by unpaired Student’s t-test.

Journal: Scientific Reports

Article Title: Atypical chemokine receptor 2 expression is directly regulated by hypoxia inducible factor-1 alpha in cancer cells under hypoxia

doi: 10.1038/s41598-024-77628-8

Figure Lengend Snippet: ACKR2 expression is decreased in B16-F10 HIFΔ tumors and associated with increased CCL5 levels. ( A ) RT-qPCR analysis of Ackr2, Ccl5, Vegfa and Ca9 gene expression in B16-F10 CTRL and HIFΔ tumors. Results are reported as fold change (FC) with error bars representing the mean ± SEM of 3 tumors per group. * = p-value < 0.05 and **** = p -value < 0.0001, determined by unpaired Student’s t-test. ( B ) Immunohistochemistry images of ACKR2 and CCL5 staining (in red), in B16-F10 CTRL and HIFΔ tumors used in ( A ). Scale bars: 200 μm. ( C ) Quantification of ACKR2 and CCL5 staining by immunohistochemistry on B16-F10 CTRL and HIFΔ tumors described in ( A ) and ( B ). Results are reported as percentage of positively stained cells relative to total cell count. For quantification, three random areas of three tumors per group were analyzed and averaged. Error bars represent the mean ± SEM of 3 tumors per group. * = p -value < 0.05 determined by unpaired Student’s t-test.

Article Snippet: ELISAs were performed using DuoSet ELISA Ancillary Reagent Kit 2 (R&D Systems, DY008B) and Mouse CCL5/RANTES DuoSet ELISA (R&D Systems, DY478) following the protocol provided by the supplier.

Techniques: Expressing, Quantitative RT-PCR, Immunohistochemistry, Staining, Cell Counting

The Arf1 inhibitors promote T-cell infiltration by upregulating CCL5 chemokine. (a) Chord diagram of gene correlation in the Arf1-ablated MYC-ON liver tumors ( n = 4 in each group). (b) qRT-PCR for chemokines in CT26 cells treated with DMSO, DU101, or DU102. (c) Serum CCL5 levels in the CT26 allografts with the indicated treatments ( n = 6 in each group). (d) CCL5 mRNA levels in the liver tumors of MYC-ON mice that were treated with DMSO, DU101, or DU102 ( n = 9 in each group). (e) Experimental design for the co-culture system. (f) FACS analysis of the migration of CD3 + T cells in CT26 cells that were treated with DMSO, DU101, or DU102. (g) The mRNA levels of CCL5 in CT26 cells with the indicated knockdowns and treatments. (h) FACS analysis of CD3 + T-cell migration in CT26 cells with the indicated knockdowns and treatments. (i and j) Tumor volumes (i) and tumor weights (j) of CT26 allografts with the indicated knockdowns and treatments ( n = 10 in each group). (k) Percentages of infiltrated CD3 + T cells in CT26 allografts with the indicated knockdowns and treatments ( n = 3 in each group). Data are shown as mean ± SEM. Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. n.s., no significance.

Journal: Life Metabolism

Article Title: Blockade of Arf1-mediated lipid metabolism in cancers promotes tumor infiltration of cytotoxic T cells via the LPE-PPARγ-NF-κB-CCL5 pathway

doi: 10.1093/lifemeta/load036

Figure Lengend Snippet: The Arf1 inhibitors promote T-cell infiltration by upregulating CCL5 chemokine. (a) Chord diagram of gene correlation in the Arf1-ablated MYC-ON liver tumors ( n = 4 in each group). (b) qRT-PCR for chemokines in CT26 cells treated with DMSO, DU101, or DU102. (c) Serum CCL5 levels in the CT26 allografts with the indicated treatments ( n = 6 in each group). (d) CCL5 mRNA levels in the liver tumors of MYC-ON mice that were treated with DMSO, DU101, or DU102 ( n = 9 in each group). (e) Experimental design for the co-culture system. (f) FACS analysis of the migration of CD3 + T cells in CT26 cells that were treated with DMSO, DU101, or DU102. (g) The mRNA levels of CCL5 in CT26 cells with the indicated knockdowns and treatments. (h) FACS analysis of CD3 + T-cell migration in CT26 cells with the indicated knockdowns and treatments. (i and j) Tumor volumes (i) and tumor weights (j) of CT26 allografts with the indicated knockdowns and treatments ( n = 10 in each group). (k) Percentages of infiltrated CD3 + T cells in CT26 allografts with the indicated knockdowns and treatments ( n = 3 in each group). Data are shown as mean ± SEM. Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. n.s., no significance.

Article Snippet: The level of chemokine CCL5 in cultured medium and mouse serum was detected by Mouse RANTES ELISA Kit (BOSTER, Cat# EK0495) according to the manufacturer’s instructions.

Techniques: Quantitative RT-PCR, Co-Culture Assay, Migration

The Arf1 inhibitors activate the PPARγ pathway by inducing unsaturated fatty acid (LPE). (a) Heatmap of different lipid fractions in the Arf1-deficient CT26 cells. (b) The mRNA levels of downstream genes of PPARγ were detected in CT26 cells treated with different concentrations of LPE (0, 100, 200, 250, and 300 μmol/L for 24 h) by qRT-PCR. (c and d) The mRNA levels of PPARγ in CT26 cells (c) and MYC-ON liver tumors (d) treated with DMSO or Arf1 inhibitors were detected by qRT-PCR. (e) The CCL5 mRNA levels in CT26 cells treated with different concentrations of LPE were detected by qRT-PCR. (f) The CCL5 mRNA levels in CT26 cells with vesicle or GW9662 treatment were detected by qRT-PCR. (g) The CCL5 levels in cell medium collected from CT26 cells with the indicated treatments were determined by ELISA. (h) The percentages of the infiltrated CD3 + T cells in CT26 cells with the indicated treatments. Data are shown as mean ± SEM. Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. n.s., no significance.

Journal: Life Metabolism

Article Title: Blockade of Arf1-mediated lipid metabolism in cancers promotes tumor infiltration of cytotoxic T cells via the LPE-PPARγ-NF-κB-CCL5 pathway

doi: 10.1093/lifemeta/load036

Figure Lengend Snippet: The Arf1 inhibitors activate the PPARγ pathway by inducing unsaturated fatty acid (LPE). (a) Heatmap of different lipid fractions in the Arf1-deficient CT26 cells. (b) The mRNA levels of downstream genes of PPARγ were detected in CT26 cells treated with different concentrations of LPE (0, 100, 200, 250, and 300 μmol/L for 24 h) by qRT-PCR. (c and d) The mRNA levels of PPARγ in CT26 cells (c) and MYC-ON liver tumors (d) treated with DMSO or Arf1 inhibitors were detected by qRT-PCR. (e) The CCL5 mRNA levels in CT26 cells treated with different concentrations of LPE were detected by qRT-PCR. (f) The CCL5 mRNA levels in CT26 cells with vesicle or GW9662 treatment were detected by qRT-PCR. (g) The CCL5 levels in cell medium collected from CT26 cells with the indicated treatments were determined by ELISA. (h) The percentages of the infiltrated CD3 + T cells in CT26 cells with the indicated treatments. Data are shown as mean ± SEM. Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. n.s., no significance.

Article Snippet: The level of chemokine CCL5 in cultured medium and mouse serum was detected by Mouse RANTES ELISA Kit (BOSTER, Cat# EK0495) according to the manufacturer’s instructions.

Techniques: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay

The Arf1 inhibitors promote T-cell tumor infiltration by activating the NF-κB-CCL5 pathway. (a) The phosphorylated p65 in CT26 cells treated with vesicle, DU101, or DU102 was detected by western blot analysis. (b) The phosphorylated p65 in MYC-ON liver tumors after DMSO, DU101, or DU102 treatment was detected by IHC staining. The right was the statistical analysis of p-p65 + cells per field. (c) The relative CCL5 enrichment in CT26 cells with the indicated treatments was analyzed by ChIP-PCR assay. (d) The CCL5 mRNA levels in CT26 cells with the indicated treatments were detected by qRT-PCR. (e) The CCL5 levels in the cell medium collected from CT26 cells with the indicated treatments were detected by the mouse CCL5 ELISA kit. (f) FACS analysis of the infiltrated CD3 + T cells in CT26 cells with the indicated treatments. (g and h) The proportions of the infiltrated CD3 + T cells (g) and CD3 + CCR5 + T (h) cells in Hepa1-6 cells with the indicated treatments were detected by FACS analysis. Data are shown as mean ± SEM. Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. n.s., no significance.

Journal: Life Metabolism

Article Title: Blockade of Arf1-mediated lipid metabolism in cancers promotes tumor infiltration of cytotoxic T cells via the LPE-PPARγ-NF-κB-CCL5 pathway

doi: 10.1093/lifemeta/load036

Figure Lengend Snippet: The Arf1 inhibitors promote T-cell tumor infiltration by activating the NF-κB-CCL5 pathway. (a) The phosphorylated p65 in CT26 cells treated with vesicle, DU101, or DU102 was detected by western blot analysis. (b) The phosphorylated p65 in MYC-ON liver tumors after DMSO, DU101, or DU102 treatment was detected by IHC staining. The right was the statistical analysis of p-p65 + cells per field. (c) The relative CCL5 enrichment in CT26 cells with the indicated treatments was analyzed by ChIP-PCR assay. (d) The CCL5 mRNA levels in CT26 cells with the indicated treatments were detected by qRT-PCR. (e) The CCL5 levels in the cell medium collected from CT26 cells with the indicated treatments were detected by the mouse CCL5 ELISA kit. (f) FACS analysis of the infiltrated CD3 + T cells in CT26 cells with the indicated treatments. (g and h) The proportions of the infiltrated CD3 + T cells (g) and CD3 + CCR5 + T (h) cells in Hepa1-6 cells with the indicated treatments were detected by FACS analysis. Data are shown as mean ± SEM. Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. n.s., no significance.

Article Snippet: The level of chemokine CCL5 in cultured medium and mouse serum was detected by Mouse RANTES ELISA Kit (BOSTER, Cat# EK0495) according to the manufacturer’s instructions.

Techniques: Western Blot, Immunohistochemistry, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay